PPAR激动剂罗格列酮对人子宫肌瘤细胞影响.doc

PPAR激动剂罗格列酮对人子宫肌瘤细胞影响[摘要] 目的 探讨过氧化物酶体增殖物激活受体(PPARγ)激动剂罗格列酮(ROT)对人子宫肌瘤的增值抑制作用及分子机制。方法 给予原代培养的子宫肌瘤不同浓度的罗格列酮处理,以四甲基偶氮唑盐微量酶反应比色(MTT)法测定细胞生长抑制率;以半定量逆转录聚合酶链反应(RT-PCR)法检测PPARγmRNA 以及凋亡基因Bax、Bcl-2 在子宫肌瘤细胞中的表达及罗格列酮对子宫肌瘤细胞增殖活化的影响。结果 罗格列酮可抑制体外培养的人子宫肌瘤细胞增殖,呈时间和剂量依赖性。RT-PCR 提示罗格列酮可促进PPARγmRNA、Bax表达,抑制Bcl-2表达。结论 过氧化物酶增殖物激活受体激动剂罗格列酮抑制子宫肌瘤的增值可能是通过上调PPARγ、Bax 的表达及下调Bcl-2 的表达来发挥作用的。 [关键词] 过氧化物酶增殖物激活受体γ; 罗格列酮; 子宫肌瘤细胞; 凋亡 [中图分类号] R730 [文献标识码] A [文章编号] 1673-9701(2010)09-07-04 Influence of Peroxisome Proliferator-activated Receptor Activator on Human Uterine Leiomyoma Cells QIN Zhongfang1* LI Meirong2△ LIU Tao1 1.Shanxi Medical University,Taiyuan 030001,China;2.The First Clinical Hospital of Shanxi Medical University,Taiyuan 030001,China [Abstrct] ObjectiveTo explore the inhibitive effect of a peroxisome proliferator activated receptor -γ(PPARγ) activator rosiglitazone on leiomyoma cell growth and its molecular mechanism. MethodsHuman leimyoma cells in vitro cultured were treated with different concentrations of rosiglitazone,and MTT assay was used to detect the growth inhibition. The semiquantitative RT-PCR method was used to detect the expression of PPARγm RNA,Bax and Bcl-2 and the effect of rosiglitazone on the proliferation and activation of leiomyoma cells. ResultsRosiglitazone inhibited the in vitro cultured human uterine leiomyoma cell proliferation in a time-and dose-dependent manner. The RT-PCR showed that rosiglitazone promoted the expression of the PPARγm RNA and Bax,and at the same time inhibited the expression of Bcl-2.ConclusionThe PPAR-γ activator,rosiglitazone,inhibits the cell proliferation partly through the up-regulation of PPAR-γand Bax and the down-regulation of Bcl-2 expression. [Key words]Peroxisome proliferators-activated receptorγ; Rosiglitazone; Leiomyoma; Apoptosis 过氧化酶体激活物增殖受体(PPAR)属于配体激活的转录因子,共分三个亚型:PPARα、PPARβ和PPARγ。PPARγ 是当前核受体方面研究的热点,除具有促进脂肪形成及抗炎作用外,还有抑制肿瘤细胞增殖的作用。许多研究结果表明PPARγ 激活后可抑制肿瘤细胞增值及促进细胞凋亡[1]。罗格列酮(Rosiglitazone,ROZ)是PPARγ 的合成